Our Integrated Platform
In Silico → In Vitro →
In Vivo Flywheel
An AI-powered discovery engine that predicts, validates, and optimizes small molecules for cell rejuvenation — each cycle improving on the last.
In Silico
Target Discovery
Proprietary AI models identify the molecular drivers of cellular exhaustion — mapping which proteins to modulate to restore function.
Compound Discovery
Screening vast molecular libraries against those targets to find small molecules with high selectivity and low off-target interactions.
In Vitro
Compound Validation
Rapid biological validation using human T cells, with standardized assays measuring polyfunctionality, exhaustion markers, and proliferative capacity.
In Vivo
Preclinical Validation
Testing in animal models to confirm that compound-enhanced T cells maintain their improved function in living systems.
Because our compounds wash out before infusion, they can enter the clinic as a CMC modification of existing CAR-T programs, starting with Baylor College of Medicine.
Results
Example of how dysfunctional T cells can be reprogrammed ex vivo and in vivo to recover function. Results first obtained in HIV and replicated in chronic hepatitis; the same mechanism we now apply to T cells during CAR-T manufacturing.
Our lead compound achieved a 6.6x increase in T cell polyfunctionality (52.8% vs 8% baseline), a 50 to 60% rise in TCF-1, and 2x antitumor capacity in vitro against MUC1+ triple-negative breast cancer cells. Cytotoxicity was confirmed at BCM (Houston) and IDCBIS (Bogotá). The compound acts during CAR-T manufacturing and washes out before the cells reach the patient; the reprogrammed state persists.
